The Platform Group AG Enhances Its Market Position with Strategic Acquisitions

The Platform Group AG (TPG) has raised its mid-term guidance, reflecting recent strategic acquisitions. The company aims for a target price of EUR 21.00, increasing from the previous EUR 19.00. These acquisitions include key stakes in Pharmosan Group, Vamida Versandapotheke, and Apothekia, complementing an already extensive pharmacy value chain.

TPG anticipates its new pharma acquisitions to generate €130 million in sales for FY’26, with an EBITDA margin of 7-8%. Additionally, plans to enter the optics and hearing market could bolster profitability, targeting impressive EBITDA margins of around 25%.

Looking ahead, the mid-term target has been adjusted to over €1 billion in revenue and €70-80 million in adjusted EBITDA for FY’26. The first impressions of these deals underline TPG's strategy to solidify its footing across multiple sectors in the healthcare market.